Business Investment Opportunities in Netherlands

We are an officially designated Qualified Representative Entity under the EU Representative Actions Directive. Our foundation has the RAD legal standing to file mass claims on behalf of millions of European consumers without needing individual mandates in every EU jurisdiction. We are currently managing both summary/emergency proceedings as well as full-blown damages compensation claims in The Netherlands, Belgium, France, Germany, Denmark and Italy and we are working to expand further within the EU. While our foundation is built on enforcing EU Market Abuse and Privacy (GDPR) rights, our newest litigation strategy actively targets violations under the Digital Services Act (DSA), the Digital Markets Act (DMA) and the EU AI Act. We also seek to expand in the areas of Product Liability and Intellectual Property claims. This allows us to hold Big Tech accountable not just for data theft, but also for algorithmic manipulation, illegal profiling, and online safety failures. Proprietary LegalTech: Unlike traditional claim foundations, our services are powered by our proprietary app. This technology serves as a scalable "lead generator" and evidence-gathering tool, enabling us to efficiently verify thousands of claimants and substantiate damages with concrete data obtained from crowd resourcing our 200,000+ participant base. Investment Proposition: we offer investors the opportunity to fund any claim of choice as offered for financing on our website. Due to our "rinse and repeat" strategy of expanding and updating claims over various jurisdictions, we offer financing opportunities that are (a) fixed in size and duration, (b) less capital intensive than would normally be the case in litigation funding. For investments amounts as of EUR 250,000 (upfront) the investor will secure entitlement of up to 20% of total damages recovered or, alternatively, to a maximum of 6x the amounts invested (no cure no pay).

We are an officially designated Qualified Representative Entity under the EU Representative Actions Directive. Our foundation has the RAD legal standing to file mass claims on behalf of millions of European consumers without needing individual mandates in every EU jurisdiction. We are currently managing both summary/emergency proceedings as well as full-blown damages compensation claims in The Netherlands, Belgium, France, Germany, Denmark and Italy and we are working to expand further within the EU. While our foundation is built on enforcing EU Market Abuse and Privacy (GDPR) rights, our newest litigation strategy actively targets violations under the Digital Services Act (DSA), the Digital Markets Act (DMA) and the EU AI Act. We also seek to expand in the areas of Product Liability and Intellectual Property claims. This allows us to hold Big Tech accountable not just for data theft, but also for algorithmic manipulation, illegal profiling, and online safety failures. Proprietary LegalTech: Unlike traditional claim foundations, our services are powered by our proprietary app. This technology serves as a scalable "lead generator" and evidence-gathering tool, enabling us to efficiently verify thousands of claimants and substantiate damages with concrete data obtained from crowd resourcing our 200,000+ participant base. Investment Proposition: we offer investors the opportunity to fund any claim of choice as offered for financing on our website. Due to our "rinse and repeat" strategy of expanding and updating claims over various jurisdictions, we offer financing opportunities that are (a) fixed in size and duration, (b) less capital intensive than would normally be the case in litigation funding. For investments amounts as of EUR 250,000 (upfront) the investor will secure entitlement of up to 20% of total damages recovered or, alternatively, to a maximum of 6x the amounts invested (no cure no pay).

Our well established orthopedic center currently caters to 15 patients daily. - We were certified in 2021 by the Ministry of Health and we have treated 3500 clients so far. - In Colombia, 95% of the people are insured, healthcare insurance companies pay for the services and our products. - We are the only clinic active in the whole province and aim to create better access to care in other regions of the country as well, decentralizing and professionalizing care. The business model: - Our orthopedic care centers in Colombia are franchisee branches and have paid a one-time brand fee. - We have received a subsidy from the Dutch government and 2 donations from NGOs. - We received equity from a public-private fund and from an individual investor.

We distinguish ourselves in making buildings more sustainable and guiding the entire process. We can no longer handle new requests, but we would like to. - A growth of more than 50% (revenue) based on last year. - Currently catering to more than 10 clients. - We focus on clients from the center of the Netherlands radius of 50km. - We have clients mostly from the internet and marketing strategies from different lead generators. - Have good relationships with partners within construction industry. - Our sales have increased due to the completion of more projects compared to last year. - Have 30 contracted-based certified professionals working with us.

Updates on the business: The facility will have growing/extraction/distillation/packaging and R&D lab facilities in order to follow the entire stage of production from mother plants to crystallized forms of stand-alone cannabinoids. The intended R&D lab will be almost 200 sq. m. and will allow us to study lesser-known cannabinoids, and after the start of construction, we are going to sign the 'Partnership Joint Research' program with Athens University. Currently have signed a partnership agreement with a running pharmaceutical company on product supply + joint research program. Later on, we will focus on the distribution channels in each country of presence in order to be prepared to scale to the B2C market with potential own generic medicine and potentially edibles, but that will be decided by the market needs and legislation. We have received an installation license for such end products and as the project progresses we will add new products to the list: - Dried hemp flower > 0.2% THC in the form of teabag (tea bag) for oral consumption; - Hemp oil in drops for oral consumption > 0.2% THC; - Hemp oil for sublingual oral consumption (spray) > 0.2% THC; - Soft cannabis capsules for oral consumption > 0.2% THC; - Capsules with dried hemp blossom > 0.2% THC in powder form for oral consumption. At the moment we have: License and permits; Architectural and engineering plans; Purchase offers from equipment suppliers; All described production processes and laboratories; Long-term land lease for 30+ years with first an option of first to purchase it; Long-term lease and right of build on the neighboring land for the second stage of construction; The entire legal structure of the holding; Verification of processes and architectural solutions under EU GACP & EU GMP standards. By the end of last year have applied for the state subsidy of EUR 3.5mil and have the option to apply for the second state subsidy next year. Additionally, the project has a right for setting fixed corporate tax for the next 12 years. Overall the production facility is projected to grow 6.5+ tons of dried biomaterial (running at 70% capacity) on a single-tier growing table with the ability of scale and potential purchase of third-party biomaterial certified by GACP standards. The EU GMP Laboratory is projected to produce 2+ tons of fine oil with an option of scaling by putting a second processing line. Additionally, the project is built in mind with an option for a second-stage expansion through the building of an additional production site on the neighboring land.